Haemonetics (HAZ) Stock Overview
A medical technology company, provides a suite of hospital technologies solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HAZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Haemonetics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.50 |
| 52 Week High | US$73.50 |
| 52 Week Low | US$39.80 |
| Beta | 0.53 |
| 1 Month Change | 7.92% |
| 3 Month Change | 5.83% |
| 1 Year Change | -4.39% |
| 3 Year Change | -28.76% |
| 5 Year Change | 19.52% |
| Change since IPO | 161.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| HAZ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 13.1% | 3.5% | 3.9% |
| 1Y | -4.4% | -27.5% | 2.6% |
Return vs Industry: HAZ exceeded the German Medical Equipment industry which returned -28.7% over the past year.
Return vs Market: HAZ underperformed the German Market which returned 1.2% over the past year.
Price Volatility
| HAZ volatility | |
|---|---|
| HAZ Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: HAZ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HAZ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 3,009 | Chris Simon | www.haemonetics.com |
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.
Haemonetics Corporation Fundamentals Summary
| HAZ fundamental statistics | |
|---|---|
| Market cap | €2.56b |
| Earnings (TTM) | €83.59m |
| Revenue (TTM) | €1.15b |
Is HAZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAZ income statement (TTM) | |
|---|---|
| Revenue | US$1.33b |
| Cost of Revenue | US$541.16m |
| Gross Profit | US$792.87m |
| Other Expenses | US$695.56m |
| Earnings | US$97.31m |
Last Reported Earnings
Mar 28, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.14 |
| Gross Margin | 59.43% |
| Net Profit Margin | 7.29% |
| Debt/Equity Ratio | 153.8% |
How did HAZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 04:32 |
| End of Day Share Price | 2026/05/25 00:00 |
| Earnings | 2026/03/28 |
| Annual Earnings | 2026/03/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haemonetics Corporation is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |
| Raymond Myers | Benchmark Company |